Disease-specific composite measures for psoriatic arthritis are highly responsive to a Janus kinase inhibitor treatment that targets multiple domains of disease

Disease-specific composite measures for psoriatic arthritis are highly responsive to a Janus kinase inhibitor treatment that targets multiple domains of disease

<h4>Background</h4> <p>The multiple disease domains affected in psoriatic arthritis (PsA) may make composite endpoints appropriate for assessing changes in disease activity over time. Tofacitinib is an oral Janus kinase inhibitor for the treatment of PsA. Data from two phase 3 stu...

Descripció completa

Dades bibliogràfiques
Autors principals:	Helliwell, P, Coates, L, Fitzgerald, O, Nash, P, Soriano, E, Husni, M, Hsu, M, Kanik, K, Hendrikx, T, Wu, J, Kudlacz, E
Format:	Journal article
Publicat:	BioMed Central 2018

Ítems similars

Disease-specific composite measures for psoriatic arthritis are highly responsive to a Janus kinase inhibitor treatment that targets multiple domains of disease
per: Philip Helliwell, et al.
Publicat: (2018-10-01)

Tofacitinib improves composite endpoint measures of disease in patients with psoriatic arthritis
per: Helliwell, P, et al.
Publicat: (2018)

Safety and efficacy of tofacitinib, an oral janus kinase inhibitor, up to 36 months in patients with active psoriatic arthritis: data from the third interim analysis of opal balance, an open-label, long-term extension study
per: Nash, P, et al.
Publicat: (2018)

Safety and efficacy of Tofacitinib, an oral Janus Kinase inhibitor, up to 36 Months in patients with active Psoriatic Arthritis: data from the third interim analysis of OPAL balance, an Open-Label, long-term extension study
per: Nash, P, et al.
Publicat: (2018)

Janus kinase inhibitors in the treatment of psoriatic arthritis
per: E. Yu. Loginova, et al.
Publicat: (2022-02-01)

Psoriasis, psoriatic arthritis, and rheumatoid arthritis: Is all inflammation the same?
per: Coates, L, et al.
Publicat: (2016)

Assessing disease activity in psoriatic arthritis: a literature review
per: Tucker, L, et al.
Publicat: (2018)

A novel treatment for psoriatic arthritis: Janus kinase inhibitors
per: Miao Chen, et al.
Publicat: (2020-04-01)

Sustained very low disease activity and remission in psoriatic arthritis patients
per: Lubrano, E, et al.
Publicat: (2019)

Current concepts and unmet needs in psoriatic arthritis
per: Mahmood, F, et al.
Publicat: (2017)

Efficacy of tofacitinib for the treatment of psoriatic arthritis: pooled analysis of two phase 3 studies
per: Nash, P, et al.
Publicat: (2018)

Remission in psoriatic arthritis—where are we now?
per: Coates, L, et al.
Publicat: (2017)

THE DIAGNOSIS OF PSORIATIC ARTHRITIS
per: P.S. Helliwell
Publicat: (2011-09-01)

Sustained Very Low Disease Activity and Remission in Psoriatic Arthritis Patients
per: Ennio Lubrano, et al.
Publicat: (2019-08-01)

Guselkumab provides durable improvement across psoriatic arthritis disease domains: post hoc analysis of a phase 3, randomised, double-blind, placebo-controlled study
per: Coates, LC, et al.
Publicat: (2024)

Relationships between psoriatic arthritis composite measures of disease activity with patient-reported outcomes in Phase 3 studies of tofacitinib
per: Coates, L, et al.
Publicat: (2021)

Ixekizumab makes very low disease activity and remission with psoriatic arthritis disease activity score possible in active psoriatic arthritis patients for up to 1 year: spirit-p1 and spirit-p2 trials
per: Coates, L, et al.
Publicat: (2018)

Best-practice indicators in Psoriatic disease care
per: Helliwell, P, et al.
Publicat: (2019)

New GRAPPA recommendations for the management of psoriasis and psoriatic arthritis: process, challenges and implementation
per: Coates, L, et al.
Publicat: (2016)

What should be the primary target of "treat to target" in psoriatic arthritis?
per: Coates, LC, et al.
Publicat: (2018)

Efficacy of Tofacitinib for the Treatment of Psoriatic Arthritis: Pooled Analysis of Two Phase 3 Studies
per: Peter Nash, et al.
Publicat: (2018-11-01)

Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active psoriatic arthritis (EQUATOR): results from a randomised, placebo-controlled, phase 2 trial
per: Mease, P, et al.
Publicat: (2018)

Psoriatic arthritis
per: FitzGerald, O, et al.
Publicat: (2021)

Relationships between psoriatic arthritis composite measures of disease activity with patient-reported outcomes in phase 3 studies of tofacitinib
per: Laura C. Coates, et al.
Publicat: (2021-03-01)

Efficacy and safety of Janus kinase inhibitors in the treatment of psoriasis and psoriatic arthritis: An analysis of evidence from 2014 to 2022
per: Jiao Wang, et al.
Publicat: (2025-02-01)

Treat-to-target in psoriatic arthritis—cost-effective in the biosimilar era
per: Coates, L, et al.
Publicat: (2022)

GRAPPA 2021 treatment recommendations for psoriatic arthritis
per: Soriano, ER, et al.
Publicat: (2023)

Psoriatic Arthritis: A Review
per: Farrouq Mahmood, et al.
Publicat: (2016-07-01)

Evaluation and validation of a patient completed psoriatic arthritis flare questionnaire
per: Helliwell, PS, et al.
Publicat: (2021)

Nail disease in psoriatic arthritis. Data from the Russian Psoriatic Arthritis Registry
per: E. E. Gubar, et al.
Publicat: (2021-10-01)

Guselkumab provides durable improvement across psoriatic arthritis disease domains: post hoc analysis of a phase 3, randomised, double-blind, placebo-controlled study
per: Laure Gossec, et al.
Publicat: (2024-02-01)

How should we define disease and outcomes in axial psoriatic arthritis?
per: Coates, LC
Publicat: (2021)

Hot topice debate: preventing psoriatic arthritis in patients with psoriasis
per: Vivekanantham, A, et al.
Publicat: (2024)

Measuring outcomes in psoriatic arthritis
per: Ogdie, A, et al.
Publicat: (2020)

Janus Kinase (JAK) Inhibitors in Rheumatoid Arthritis
per: Vishal R. Tandon, et al.
Publicat: (2022-07-01)

Axial spondyloarthritis and psoriatic arthritis: mostly overlapping or substantially different diseases?
per: Braun, J, et al.
Publicat: (2023)

Real‐World Evidence Assessing Psoriatic Arthritis by Disease Domain: An Evaluation of the CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry
per: Philip J. Mease, et al.
Publicat: (2023-08-01)

Association between patient perception of disease status and different components of the Minimal Disease Activity (MDA) criteria in psoriatic arthritis
per: Yazji, SM, et al.
Publicat: (2025)

Safety and efficacy of tofacitinib up to 48 months in patients with active psoriatic arthritis: final analysis of the OPAL Balance long-term extension study
per: Nash, P, et al.
Publicat: (2021)

Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA): updated treatment recommendations for psoriatic arthritis 2021
per: Coates, LC, et al.
Publicat: (2022)